Gut Microbiota, Microbial Metabolites, and Growth Trajectories in Fetal Growth Restriction and Small for Gestational Age Infants: A Structured Narrative Review of the First 1000 Days
- 1Grigore T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
- 2Clinical Medical Department, Faculty of Medicine and Pharmacy, “Dunarea de Jos” University of Galati, 800008 Galati, Romania
Abstract
Background/Objectives: Fetal growth restriction (FGR) and small for gestational age (SGA) status are related but distinct entities, both linked to increased long-term cardiometabolic risk, potentially mediated by the gut microbiome–metabolome axis during the first 1000 days of life. This review synthesizes current evidence on gut dysbiosis, host and microbial metabolites, catch-up growth, and probiotic interventions in these populations. Methods: A structured narrative review of human and animal studies published in English between January 2010 and August 2026 was conducted across PubMed/MEDLINE, Embase, Scopus, and Web of Science. Results: Reported alterations in gut microbial composition and function are heterogeneous, without a single, consistently replicated taxonomic signature, and much of the evidence derives from SGA or preterm cohorts rather than antenatally confirmed FGR. Metabolomic studies recurrently implicate host amino-acid, acylcarnitine, and phospholipid pathways, but small samples, heterogeneous platforms, and incomplete reporting of metabolite identification, normalization, and gestational age at sampling limit comparability. Mechanistic animal studies support selected pathways linking maternal dysbiosis to placental dysfunction, though the full sequence from early microbial alterations to catch-up growth and cardiometabolic risk remains unproven in humans. Gut microbial diversity has been associated with catch-up weight gain in one small SGA cohort, and delayed microbiota maturation with postnatal growth failure in some, but not all, preterm cohorts. Evidence from preterm populations supports benefits of selected probiotic preparations for some neonatal outcomes, while effects on short-term growth are modest and heterogeneous; probiotics have not been shown to modify catch-up-growth quality or long-term cardiometabolic outcomes after FGR, and safety and efficacy appear product-, strain-, and population-specific. Conclusions: Current evidence supports plausible, partially demonstrated mechanistic links between FGR/SGA, gut dysbiosis, and cardiometabolic programming, but not a fully validated causal pathway in humans. Future studies should distinguish FGR from SGA, assess body composition alongside growth, and evaluate product-specific probiotic efficacy and safety with long-term follow-up.
Related
- Maternal Angiogenic Profiles in Preeclampsia-Associated Versus Isolated Fetal Growth Restriction or Small-for-Gestational-Age Pregnancies: A Systematic Review and Meta-Analysis
- Natural Compounds and Their Microbiota-Derived Metabolites as Modulators of the Microbiota–Gut–Brain Axis in Alzheimer Disease: Biochemical Mechanisms and Drug Discovery Insights—A Narrative Review
- TMAO at the Crossroads of the Gut–Brain Axis: Emerging Mechanisms Linking Microbiota-Derived Metabolites to Neuroinflammation and Cognitive Dysfunction
- Integrating early-life gut microbiota with maternal–infant clinical data to classify mild head-circumference restriction at one month
- Paeonidin- and Cyanidin-Rich Fractions Ameliorate Gut Microbiota and Serum Metabolites in Rats with Type 2 Diabetes
BibTeX
@article{adamraileanu2026microbiota,
title = {{Gut Microbiota, Microbial Metabolites, and Growth Trajectories in Fetal Growth Restriction and Small for Gestational Age Infants: A Structured Narrative Review of the First 1000 Days}},
author = {Anca Adam-Raileanu and Emil Anton and Magdalena Cuciureanu and Ancuta Lupu and Elena Jechel and Leonard Iosif Pertea and Laura Iulia Bozomitu and Oana Raluca Temneanu and Lorenza Forna and Ioana Alecsandra Munteanu and Anastasia Chirvasa and Silvia Fotea and Sorana Caterina Anton and Alin Horatiu Nedelcu and Vasile Valeriu Lupu},
journal = {Metabolites},
year = {2026},
month = nov,
doi = {10.3390/metabo16110853},
url = {https://www.mdpi.com/2218-1989/16/11/853},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gut Microbiota, Microbial Metabolites, and Growth Trajectories in Fetal Growth Restriction and Small for Gestational Age Infants: A Structured Narrative Review of the First 1000 Days
AU - Anca Adam-Raileanu
AU - Emil Anton
AU - Magdalena Cuciureanu
AU - Ancuta Lupu
AU - Elena Jechel
AU - Leonard Iosif Pertea
AU - Laura Iulia Bozomitu
AU - Oana Raluca Temneanu
AU - Lorenza Forna
AU - Ioana Alecsandra Munteanu
AU - Anastasia Chirvasa
AU - Silvia Fotea
AU - Sorana Caterina Anton
AU - Alin Horatiu Nedelcu
AU - Vasile Valeriu Lupu
PY - 2026
DA - 2026/11/04
JO - Metabolites
DO - 10.3390/metabo16110853
UR - https://www.mdpi.com/2218-1989/16/11/853
AB - Background/Objectives: Fetal growth restriction (FGR) and small for gestational age (SGA) status are related but distinct entities, both linked to increased long-term cardiometabolic risk, potentially mediated by the gut microbiome–metabolome axis during the first 1000 days of life. This review synthesizes current evidence on gut dysbiosis, host and microbial metabolites, catch-up growth, and probiotic interventions in these populations. Methods: A structured narrative review of human and animal studies published in English between January 2010 and August 2026 was conducted across PubMed/MEDLINE, Embase, Scopus, and Web of Science. Results: Reported alterations in gut microbial composition and function are heterogeneous, without a single, consistently replicated taxonomic signature, and much of the evidence derives from SGA or preterm cohorts rather than antenatally confirmed FGR. Metabolomic studies recurrently implicate host amino-acid, acylcarnitine, and phospholipid pathways, but small samples, heterogeneous platforms, and incomplete reporting of metabolite identification, normalization, and gestational age at sampling limit comparability. Mechanistic animal studies support selected pathways linking maternal dysbiosis to placental dysfunction, though the full sequence from early microbial alterations to catch-up growth and cardiometabolic risk remains unproven in humans. Gut microbial diversity has been associated with catch-up weight gain in one small SGA cohort, and delayed microbiota maturation with postnatal growth failure in some, but not all, preterm cohorts. Evidence from preterm populations supports benefits of selected probiotic preparations for some neonatal outcomes, while effects on short-term growth are modest and heterogeneous; probiotics have not been shown to modify catch-up-growth quality or long-term cardiometabolic outcomes after FGR, and safety and efficacy appear product-, strain-, and population-specific. Conclusions: Current evidence supports plausible, partially demonstrated mechanistic links between FGR/SGA, gut dysbiosis, and cardiometabolic programming, but not a fully validated causal pathway in humans. Future studies should distinguish FGR from SGA, assess body composition alongside growth, and evaluate product-specific probiotic efficacy and safety with long-term follow-up.
SN - 2218-1989
ER -